CA2989161A1 - Ethynylxanthines, leurs preparations et leurs utilisations pour traiter le cancer - Google Patents

Ethynylxanthines, leurs preparations et leurs utilisations pour traiter le cancer

Info

Publication number
CA2989161A1
CA2989161A1 CA2989161A CA2989161A CA2989161A1 CA 2989161 A1 CA2989161 A1 CA 2989161A1 CA 2989161 A CA2989161 A CA 2989161A CA 2989161 A CA2989161 A CA 2989161A CA 2989161 A1 CA2989161 A1 CA 2989161A1
Authority
CA
Canada
Prior art keywords
4alkyl
3alkyl
purine
dione
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2989161A
Other languages
English (en)
Other versions
CA2989161C (fr
Inventor
Pavels Arsenjans
Jelena VASILJEVA
Ilona Domracheva
Irina Shestakova
Anita GULBE
Iveta KANEPE-LAPSA
Valerjans Kauss
Ivars Kalvins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Latvian Institute of Organic Synthesis
Original Assignee
Latvian Institute of Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvian Institute of Organic Synthesis filed Critical Latvian Institute of Organic Synthesis
Publication of CA2989161A1 publication Critical patent/CA2989161A1/fr
Application granted granted Critical
Publication of CA2989161C publication Critical patent/CA2989161C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2989161A 2015-03-27 2015-03-27 Ethynylxanthines, leurs preparations et leurs utilisations pour traiter le cancer Active CA2989161C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/LV2015/000001 WO2016159745A1 (fr) 2015-03-27 2015-03-27 Ethynylxanthines, leurs préparations et leurs utilisations pour traiter le cancer

Publications (2)

Publication Number Publication Date
CA2989161A1 true CA2989161A1 (fr) 2016-10-06
CA2989161C CA2989161C (fr) 2022-03-01

Family

ID=52815227

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2989161A Active CA2989161C (fr) 2015-03-27 2015-03-27 Ethynylxanthines, leurs preparations et leurs utilisations pour traiter le cancer

Country Status (3)

Country Link
CA (1) CA2989161C (fr)
GB (1) GB2553684B (fr)
WO (1) WO2016159745A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2166948C1 (ru) 2000-05-29 2001-05-20 Центральный научно-исследовательский рентгенорадиологический институт Способ лечения глиом с эпилептическим синдромом
EP1939197A1 (fr) 2006-12-22 2008-07-02 Schwarz Pharma Ag Derivés de 8-éthinylxanthine comme antagonistes selectives du recepteur A2A
KR101610005B1 (ko) * 2007-08-17 2016-04-08 베링거 인겔하임 인터내셔날 게엠베하 Fab 관련 질환의 치료에 사용하기 위한 푸린 유도체
WO2011005871A1 (fr) * 2009-07-07 2011-01-13 Pgxhealth, Llc 8-[6-carbonylamino-3-pyridyle] xanthines substituées en tant qu’antagonistes de l’adénosine a2b
PE20151779A1 (es) 2013-03-15 2015-11-20 Hydra Biosciences Inc Xantinas sustituidas y metodos de uso de las mismas

Also Published As

Publication number Publication date
GB2553684A8 (en) 2018-04-18
GB2553684B (en) 2020-06-03
GB2553684A (en) 2018-03-14
CA2989161C (fr) 2022-03-01
WO2016159745A1 (fr) 2016-10-06

Similar Documents

Publication Publication Date Title
JP6919922B2 (ja) Fgfr4阻害剤、その製造方法と薬学的な応用
EP3719012B1 (fr) Dérivés de n-[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophényl]-3-(4-fluorophényl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxamide en tant qu'inhibiteurs de c-met/axl pour le traitement des tumeurs
JP6951767B2 (ja) 抗癌薬として使用される複素環式化合物
CA2698018C (fr) Composes tricycliques ayant une activite cytostatique et/ou cytotoxique et leurs procedes d'utilisation
JP5649614B2 (ja) 有機化合物
KR20060120393A (ko) 글리코겐 신타아제 키나제 3 저해제로서의트리아졸로피리미딘 유도체
JP7100693B2 (ja) テトラヒドロプロトベルベリン系化合物、その製造方法、使用及び医薬組成物
WO2022007841A1 (fr) Inhibiteur de l'egfr, procédé de préparation associé, et application pharmaceutique associée
JP2023145547A (ja) Cd73阻害剤、その製造方法と応用
KR20150119401A (ko) 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물
CN104557871A (zh) 具有螺环取代基的芳基吗啉类化合物,其制备方法和用途
CN104557913B (zh) 吡啶并嘧啶类化合物,其制备方法和用途
El-Gamal et al. Diarylureas and diarylamides with pyrrolo [2, 3-d] pyrimidine scaffold as broad-spectrum anticancer agents
CN111116585B (zh) 具有c-MET激酶抑制活性化合物、制备方法、组合物及用途
Bu et al. Synthesis and cytotoxic activity of N-[(alkylamino) alkyl] carboxamide derivatives of 7-oxo-7H-benz [de] anthracene, 7-oxo-7H-naphtho [1, 2, 3-de] quinoline, and 7-oxo-7H-benzo [e] perimidine
Guillonneau et al. Cytotoxic and antitumoral properties in a series of new, ring D modified, olivacine analogues
Ghoneim et al. Synthesis of some new hydroquinoline and pyrimido [4, 5-b] quinoline derivatives
ES2896938T3 (es) Inhibidores de GSK-3
CA2989161C (fr) Ethynylxanthines, leurs preparations et leurs utilisations pour traiter le cancer
Costa et al. Synthesis of novel chromene scaffolds for adenosine receptors
EP3036227B1 (fr) Procédé pour préparer un composé
AL-SULTANI et al. Antioxidant Activity of some New synthesised benzo [d] imidazo [2, 1-b] thiazole derivatives.
KR101035709B1 (ko) 신규2-치환아미노알킬레닐옥시-3-치환페닐에티닐-6-아미노퀴녹살린 유도체
WO2016159747A1 (fr) Éthynylxanthines, préparation et utilisation de ces composés en tant que modulateurs des canaux calciques
WO2016159746A1 (fr) Nouvelles éthynylxanthines, leur préparation et leur utilisation en tant qu'inhibiteurs de métalloprotéinases matricielles et d'angiogenèse

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200319